Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinoma

Cancers of the stomach and gastro-esophageal junction represent a significant challenge in oncology. Despite some recent advances in genetic categorization and the development of novel agents, outcomes remain poor. The vascular endothelial growth factor receptor 2 monoclonal antibody ramucirumab is...

Descripción completa

Detalles Bibliográficos
Autores principales: Davidson, Michael, Smyth, Elizabeth C, Cunningham, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966750/
https://www.ncbi.nlm.nih.gov/pubmed/27524910
http://dx.doi.org/10.2147/OTT.S84153
_version_ 1782445426362810368
author Davidson, Michael
Smyth, Elizabeth C
Cunningham, David
author_facet Davidson, Michael
Smyth, Elizabeth C
Cunningham, David
author_sort Davidson, Michael
collection PubMed
description Cancers of the stomach and gastro-esophageal junction represent a significant challenge in oncology. Despite some recent advances in genetic categorization and the development of novel agents, outcomes remain poor. The vascular endothelial growth factor receptor 2 monoclonal antibody ramucirumab is the first targeted therapy to improve survival in a molecularly unselected population, and represents a valuable new treatment option. This review describes the current treatment landscape for advanced disease, evaluates existing and ongoing research into ramucirumab, and discusses its current and potential future therapeutic role.
format Online
Article
Text
id pubmed-4966750
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-49667502016-08-12 Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinoma Davidson, Michael Smyth, Elizabeth C Cunningham, David Onco Targets Ther Review Cancers of the stomach and gastro-esophageal junction represent a significant challenge in oncology. Despite some recent advances in genetic categorization and the development of novel agents, outcomes remain poor. The vascular endothelial growth factor receptor 2 monoclonal antibody ramucirumab is the first targeted therapy to improve survival in a molecularly unselected population, and represents a valuable new treatment option. This review describes the current treatment landscape for advanced disease, evaluates existing and ongoing research into ramucirumab, and discusses its current and potential future therapeutic role. Dove Medical Press 2016-07-25 /pmc/articles/PMC4966750/ /pubmed/27524910 http://dx.doi.org/10.2147/OTT.S84153 Text en © 2016 Davidson et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Davidson, Michael
Smyth, Elizabeth C
Cunningham, David
Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinoma
title Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinoma
title_full Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinoma
title_fullStr Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinoma
title_full_unstemmed Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinoma
title_short Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinoma
title_sort clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966750/
https://www.ncbi.nlm.nih.gov/pubmed/27524910
http://dx.doi.org/10.2147/OTT.S84153
work_keys_str_mv AT davidsonmichael clinicalroleoframucirumabaloneorincombinationwithpaclitaxelforgastricandgastroesophagealjunctionadenocarcinoma
AT smythelizabethc clinicalroleoframucirumabaloneorincombinationwithpaclitaxelforgastricandgastroesophagealjunctionadenocarcinoma
AT cunninghamdavid clinicalroleoframucirumabaloneorincombinationwithpaclitaxelforgastricandgastroesophagealjunctionadenocarcinoma

Ejemplares similares